As per the terms of the expanded agreement, Keith Kendall, executive vice president and chief financial officer of MonoSol Rx, is expected to join Midatech board of directors.
Midatech and MonoSol Rx said that since 2008 they have been leveraging the self-assembling glyconanoparticle and PharmFilm technologies to formulate large molecules for oral bioavailability on film.
Tom Rademacher, chairman of Midatech, said: “We believe that MonoSol Rx’s PharmFilm technology is a stable and effective vehicle for delivering a therapeutic dose of our peptide carrying nanoparticles buccally or sublingually for specific indications, thereby eliminating the need for injection or more invasive delivery.”
Mark Schobel, president and CEO of MonoSol Rx, said: “We have strengthened our collaboration with Midatech on the heels of positive data indicating the delivery of a 6000dalton polypeptide in a pre-clinical model.
“Having demonstrated that the size and chemical composition of Midatech’s biocompatible nanocarriers are suited for oral delivery using our PharmFilm technology, we are continuing to jointly research and develop nanoparticle-based oral film formulations of certain peptides that are currently limited by their need to be injected or infused.”
Mr Kendall, said: “The expansion of this agreement further solidifies the commitment between MonoSol Rx and Midatech. We also believe that our collaborations with Midatech will reap benefits as we work on our development initiatives and execute our plans to jointly file IP to protect the combination of our two technologies in the oral delivery of large molecules.”